Longeveron announced that the Canadian Intellectual Property Office (CIPO) has granted a patent (No. 3043594) covering the use of its allogeneic mesenchymal stem-cell therapy laromestrocel (Lomecel-B®) for treatment of aging-related frailty associated with “inflammaging” and for non-ischemic dilated cardiomyopathy (NIDCM).
The patent grants Longeveron exclusive method-of-use rights in Canada through 2037.
According to the company, aging-related frailty is a syndrome marked by weakness, reduced physical activity, slowed motor function, exhaustion and unintended weight loss — conditions often linked with chronic inflammation (inflammaging).
Longeveron notes that earlier Phase 1 and Phase 2 studies of laromestrocel in frailty patients demonstrated improvements in physical functioning and performance on a six-minute walk test.
For non-ischemic dilated cardiomyopathy, a progressive cardiac disease lacking a cure and often leading to transplant, the company asserts its stem-cell therapy has potential through mechanisms including immunomodulation, tissue repair, vascular support, and anti-inflammatory effects.
Longeveron said the patent strengthens its intellectual property foundation and supports long-term development and potential commercialization of laromestrocel for these indications in Canada.
